We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+17.01%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$5.66B
AUM Growth
+$1B
Cap. Flow
+$784M
Cap. Flow %
13.85%
Top 10 Hldgs %
43.17%
Holding
164
New
34
Increased
29
Reduced
25
Closed
18

Top Buys

Rank Stock Value
1
INTC icon
Intel
INTC
+$47.7M
2
ARGX icon
argenx
ARGX
+$47.4M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$44.5M
4
IMA
ImageneBio Inc
IMA
+$44.2M
5
ACHL
Achilles Therapeutics
ACHL
+$37.3M

Top Sells

Rank Stock Value
1
GDS icon
GDS Holdings
GDS
+$89.7M
2
Z icon
Zillow
Z
+$66.8M
3
ONC
BeOne Medicines Ltd
ONC
+$49.7M
4
BABA icon
Alibaba
BABA
+$46.5M
5
QURE icon
uniQure
QURE
+$25.3M

Sector Composition

Rank Sector Weight
1 Healthcare 68.71%
2 Consumer Discretionary 8.71%
3 Technology 1.72%
4 Communication Services 0.79%
5 Real Estate 0.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STOK icon
101
Stoke Therapeutics
STOK
$1.84B
$9.71M 0.17%
250,000
– –
DCPH
102
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$8.97M 0.16%
200,000
-300,000
-60% -$14M
OLMA icon
103
Olema Pharmaceuticals
OLMA
$977M
$8.64M 0.15%
260,500
– –
ARAV
104
DELISTED
Aravive, Inc. Common Stock
ARAV
$8.64M 0.15%
1,311,291
– –
IMCR icon
105
Immunocore
IMCR
$1.7B
$8.51M 0.15%
+200,000
New +$8.9M
SYRE icon
106
Spyre Therapeutics
SYRE
$8.5B
$8.28M 0.15%
41,800
– –
DYN icon
107
Dyne Therapeutics
DYN
$4.15B
$8.15M 0.14%
525,000
+225,000
+75% +$4.35M
GDS icon
108
GDS Holdings
GDS
$5.93B
$8.11M 0.14%
100,000
-900,000
-90% -$89.7M
HOOK
109
DELISTED
HOOKIPA Pharma
HOOK
$8.06M 0.14%
59,962
-35,000
-37% -$4.22M
SYRS
110
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$7.67M 0.14%
102,500
+27,500
+37% +$2.86M
ACIU icon
111
AC Immune
ACIU
$231M
$7.61M 0.13%
1,000,000
– –
APLT
112
DELISTED
Applied Therapeutics
APLT
$7.5M 0.13%
400,000
+20,000
+5% +$431K
OMEG
113
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$7.42M 0.13%
+750,000
New +$7.79M
SPRO icon
114
Spero Therapeutics
SPRO
$68.9M
$7.36M 0.13%
500,000
– –
CFRX
115
DELISTED
ContraFect Corporation
CFRX
$7.2M 0.13%
18,750
+6,250
+50% +$2.7M
CRDF icon
116
Cardiff Oncology
CRDF
$63M
$6.95M 0.12%
750,000
-150,000
-17% -$1.82M
ALPN
117
DELISTED
Alpine Immune Sciences Inc
ALPN
$6.29M 0.11%
593,030
– –
SGTX
118
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
$6.17M 0.11%
21,231
– –
FUSN
119
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$5.78M 0.1%
+539,264
New +$6.3M
MTCR
120
DELISTED
Metacrine, Inc. Common Stock
MTCR
$5.73M 0.1%
924,898
– –
CYPH
121
Cypherpunk Technologies Inc
CYPH
$64M
$5.7M 0.1%
300,000
– –
CYCN icon
122
Cyclerion Therapeutics
CYCN
$15.2M
$5.07M 0.09%
90,879
– –
MREO
123
Mereo BioPharma
MREO
$48.9M
$5.05M 0.09%
+1,500,000
New +$5.3M
CGEM icon
124
Cullinan Oncology
CGEM
$1.06B
$4.17M 0.07%
+100,000
New +$4.06M
MCRB icon
125
Seres Therapeutics
MCRB
$45M
$4.12M 0.07%
10,000
– –
3 4
5
6 7

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2021 Portfolio in Review

As of Q1 2021, Artal Group held 164 positions worth $5.66B, up 21% from $4.66B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Artal Group deployed $784M of net new capital in Q1 2021, opening 34 new positions and adding to 29 existing holdings. Its largest new stake was Intel: 800,000 shares worth $51.2M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 77% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was GDS Holdings, an estimated $89.7M trimmed.

  • Artal Group's largest Q1 2021 buy was Intel: 800,000 shares worth $51.2M.
  • Artal Group added most to argenx in Q1 2021, an estimated $47.4M increase.
  • Artal Group's biggest Q1 2021 reduction was GDS Holdings, cutting an estimated $89.7M.
  • Artal Group fully exited Alibaba in Q1 2021, selling an estimated $46.5M.
  • Artal Group's ten largest holdings make up 43% of its $5.66B portfolio in Q1 2021.
  • Artal Group opened 34 new positions and closed 18 in Q1 2021.
  • Artal Group's portfolio value rose 21% quarter-over-quarter to $5.66B.

Based on Artal Group's 13F filing for Q1 2021, filed 14 May 2021.